Merck Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 5/6

Merck kazançlarla iyi bir şekilde karşılanan, 2.99% cari getiriye sahip, temettü ödeyen bir şirkettir.

Anahtar bilgiler

3.0%

Temettü verimi

0.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	3.4%
Gelecekteki Temettü Verimi	3.2%
Temettü Büyümesi	-1.2%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	US$3.080
Ödeme oranı	63%

Son temettü ve geri alım güncellemeleri

Recent updates

Merck: An Undervalued Dividend Machine

Nov 07

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Oct 25

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 01

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: MRK şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.

Büyüyen Temettü: MRK şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

Merck Piyasaya Karşı Temettü Getirisi

MRK temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (MRK)	3.0%
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (MRK) (3 yıla kadar)	3.2%

Önemli Temettü: MRK 'in temettüsü ( 2.99% ), US piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 1.35% ) daha yüksektir.

Yüksek Temettü: MRK 'in temettüsü ( 2.99% ), US piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.36% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Makul ödeme oranı ( 63.4% ) ile MRK 'un temettü ödemeleri kazançlarla karşılanmaktadır.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Makul nakit ödeme oranı ( 59.3% ) ile MRK 'un temettü ödemeleri nakit akışları ile karşılanmaktadır.

Merck Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 5/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Upcoming dividend of US$0.77 per share

Recent updates

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Merck: An Undervalued Dividend Machine

Third quarter 2024 earnings: EPS misses analyst expectations

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

Merck Is At Support And Should Go Higher (Technical Analysis)

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Merck Appears Ready To Return To June Highs (Technical Analysis)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck's Change To Profit Guidance Provides An Opportunity

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck: Buy This Bargain Before It's Gone

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin